Key result
Intracoronary epinephrine demonstrated substantial improvement in coronary flow in patients with STEMI and refractory coronary no-reflow during primary percutaneous coronary intervention.
Why the study?
Does intracoronary epinephrine improve coronary flow in patients with ST-elevation myocardial infarction experiencing refractory coronary no-reflow during primary percutaneous coronary intervention?
Does intracoronary epinephrine improve coronary flow in patients with ST-elevation myocardial infarction experiencing refractory coronary no-reflow during primary percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
Intracoronary epinephrine is a potential therapeutic option for the serious and difficult-to-treat phenomenon of refractory coronary no-reflow during primary PCI for STEMI.
Key Points Proof‐of‐concept study demonstrates that intracoronary epinephrine could provide substantial improvement in coronary flow in ST‐elevation myocardial infarction refractory coronary no‐reflow during primary percutaneous coronary intervention. Intracoronary epinephrine is a potential solution to an uncommon but clinically serious phenomenon with limited, if any, therapeutic alternatives. A prospective, large, randomized trial, which is powered for clinical events, would help further validate this management technique.
No takes yet. Share an insight, caveat, or question.
Case et al. (2021) studied ST-elevation myocardial infarction refractory coronary no-reflow during primary percutaneous coronary intervention. Intracoronary epinephrine was evaluated on Coronary flow. Intracoronary epinephrine demonstrated substantial improvement in coronary flow in patients with STEMI and refractory coronary no-reflow during primary percutaneous coronary intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: